SANTA ROSA -- Sapheon Inc., a maker of venous disease treatments formerly based in Santa Rosa, has been sold to Covidien, a global health care company based in Dublin, Ireland.
Covidien had 2013 revenue of about $10 billion. Details of the deal were not disclosed.
“If left untreated, varicose veins can progress into a chronic and life threatening condition,” said Mark Turco, M.D., chief medical officer, Vascular Therapies, Covidien, in a statement. “The VenaSeal system is a minimally invasive technology, and unlike open surgery and other more invasive procedures, patients are often able to quickly regain their lifestyle.”